Document Detail

Inhaled treprostinil for the treatment of pulmonary arterial hypertension.
MedLine Citation:
PMID:  22135338     Owner:  NLM     Status:  MEDLINE    
Pulmonary arterial hypertension is a progressive disease characterized by vascular proliferation and vasoconstriction of the small pulmonary arteries that eventually leads to right-sided heart failure and death. Patients often initially have symptoms such as shortness of breath, fatigue, and edema; later in the disease, presyncope and syncope are common. Patients with progressive pulmonary arterial hypertension despite oral therapy and/or with severe disease typically require treatment with a prostanoid. Inhaled treprostinil (Tyvaso) is a prostacyclin analog indicated for the treatment of pulmonary arterial hypertension to increase walk distance in patients with symptoms classified as New York Heart Association functional class III. Inhaled treprostinil was approved by the Food and Drug Administration in July 2009. This article provides a brief overview of the pathophysiology of pulmonary arterial hypertension and reviews the mechanism of action, key clinical data, and the practical management of inhaled treprostinil in patients with pulmonary arterial hypertension.
Abby Poms; Martha Kingman
Related Documents :
12440658 - Reoperative cryopreserved root and ascending aorta replacement for acute aortic prosthe...
15052218 - Thromboembolic events after aortic valve replacement in elderly patients with a carpent...
19182278 - Transcatheter and transapical aortic valve replacement.
6688168 - Surgical pathology of obstructed, right-sided, porcine-valved extracardiac conduits.
7497508 - Coronary angioplasty of bifurcational lesions with the protecting branch technique usin...
20670508 - Treatment of a vertebral dissecting aneurysm with a balloon-expandable stent and guglie...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Critical care nurse     Volume:  31     ISSN:  1940-8250     ISO Abbreviation:  Crit Care Nurse     Publication Date:  2011 Dec 
Date Detail:
Created Date:  2011-12-02     Completed Date:  2012-04-26     Revised Date:  2012-05-14    
Medline Journal Info:
Nlm Unique ID:  8207799     Medline TA:  Crit Care Nurse     Country:  United States    
Other Details:
Languages:  eng     Pagination:  e1-10     Citation Subset:  N    
Duke University Medical Center, Durham, North Carolina 27710, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Inhalation
Antihypertensive Agents / administration & dosage*
Epoprostenol / administration & dosage,  analogs & derivatives*
Hypertension, Pulmonary / drug therapy*,  physiopathology
Medical Illustration
Randomized Controlled Trials as Topic
Treatment Outcome
Reg. No./Substance:
0/Antihypertensive Agents; 0/treprostinil; 35121-78-9/Epoprostenol
Erratum In:
Crit Care Nurse. 2012 Apr;32(2):11

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Using a nursing productivity committee to achieve cost savings and improve staffing levels and staff...
Next Document:  Critical care staff nurses: empowerment, certification, and intent to leave.